Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.60 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL842634 | 0.90 | SMN1; SMN2 (0.81) | L3MBTL1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL13763531 | 0.89 | L3MBTL1 (0.80) | L3MBTL1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL10085277 | 0.89 | SMN1; SMN2 (0.73) | L3MBTL1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL19254325 | 0.87 | SMN1; SMN2 (0.71) | L3MBTL1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL13763462 | 0.87 | SMN1; SMN2 (0.71) | L3MBTL1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL19254326 | 0.87 | SMN1; SMN2 (0.71) | L3MBTL1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL19124111 | 0.87 | SMN1; SMN2 (0.71) | L3MBTL1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL842631 | 0.86 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL9492626 | 0.86 | NPC1 (0.68) | L3MBTL1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1360195 | 0.86 | HDAC8 (0.65) | NPC1RAB9ASMN1; SMN2POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107667088-B | Novel benzoic acid amide compound | 株式会社爱茉莉太平洋 | 2020-04-24 | — | — | CN | claimed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| CN-118771989-A | Method for catalyzing hydrosilation reduction of amide into amine by using tridentate nitrogen ligand manganese complex | 浙江工业大学 | 2024-10-15 | — | — | CN | disclosed |
| CN-110294772-B | 2-alkyl silicon-benzamide compound and synthesis method thereof | 五邑大学 | 2021-12-28 | — | — | CN | disclosed |
| CN-110294772-A | A kind of 2- alkyl silicon-benzamide compound and its synthetic method | 五邑大学 | 2019-10-01 | — | — | CN | disclosed |
| EP-2408772-B1 | COMPOUNDS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2015-07-01 | — | — | EP | disclosed |
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2099757-B1 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20140105921-A1 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors | ONYX THERAPEUTICS, INC. | 2014-04-17 | — | — | US | disclosed |
| US-8658651-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-02-25 | — | — | US | disclosed |
| US-4157441-A | PROSTAGLANDINS, ANTIINFLAMMATORY AGENTS | THE UPJOHN COMPANY (US) | 1979-06-05 | — | — | US | disclosed |
| US-4151351-A | PROSTAGLANDINS, ANTIINFLAMMATORY | THE UPJOHN COMPANY (US) | 1979-04-24 | — | — | US | disclosed |
| US-4131738-A | 6-Hydroxy-PGE1 compounds | THE UPJOHN COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
| US-4128713-A | 6,7-Didehydro-PGI1 compounds | THE UPJOHN COMPANY (US) | 1978-12-05 | — | — | US | disclosed |
| US-4126744-A | PROSTACYCLIN, MUSCLE STIMULANTS, PLATELET AGGREGATION INHIBITORS | THE UPJOHN COMPANY (US) | 1978-11-21 | — | — | US | disclosed |
| US-4112224-A | PROSTAGLANDIN | THE UPJOHN COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4109082-A | PROSTACYCLIN ANALOGS; SMOOTH MUSCLE STIMULATORS | THE UPJOHN COMPANY (US) | 1978-08-22 | — | — | US | disclosed |
| US-4100192-A | Inter-phenylene-PG amides | THE UPJOHN COMPANY (US) | 1978-07-11 | — | — | US | disclosed |
| US-4097489-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140105921-A1 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors | PREP, VIP, PEPD | L3MBTL1 2201/4885NPC1 1001/4885RAB9A 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.